Gelnique Generic: When Will Generic Oxybutynin Be Available?

This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS

Updated October 9, 2026 How we build our data

Gelnique Generic at a Glance

Four quick answers from FDA records and our estimate.

When is the first generic expected? TBD no date yet What opens the door is not settled yet
Has the FDA approved a generic? May 2018 Since discontinued
When does the last patent end? March 2031 3 patents listed with the FDA
Can you buy a generic today? Not yet No company lists one for sale

Dr. Brian Staiger Explains

PharmD, BCPS · Clinical pharmacist Updated October 9, 2026

There is no expected month yet for generic oxybutynin chloride. None is for sale yet.

Will the generic cost less?

Usually, and more so as more companies sell one. One company has applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 31% less once one company sold a generic. See the price pattern

What should I do now?

Keep taking Gelnique as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you

Our month is only an estimate based on available information, so we never name a day.

Gelnique by the Numbers

Reason: Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
How sure: Not rated Too early to rate.
Price competition: Low 1 company has filed, 1 first in line
Brand sales: Sales not reported

FDA approved 2009 January 2009 FDA Orange Book
Patents listed 3 last runs to March 2031 FDA Orange Book

Gelnique’s Road to a Generic

Gelnique has had the market to itself since the FDA approved it in January 2009 (Abbvie Inc). Its 3 listed patents run to March 2031. Generic companies have challenged its patents with the FDA since June 2014.

The brand company and a generic maker settled their patent fight and agreed on when a generic can launch.

Brand alone on the market Since FDA approval, January 2009

Patent 9,259,388 Expires November 2029

Patent 10,449,173 Expires November 2029

Patent 8,920,392 Expires March 2031

Brand alone on the market Patent on the formulation Patent on a use Swipe the chart sideways to see every year.

Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.

Gelnique Patents and FDA Protections

Every patent and exclusivity the FDA Orange Book lists for Gelnique’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.

Patents listed with the FDA (3)
Patent	What it covers	Protects until	Status
9,259,388	A way of using it (U-1644)	November 2029	Active
10,449,173	The product’s formulation; a way of using it (U-2637)	November 2029	Active
8,920,392	A way of using it (U-1644)	March 2031	Active

Source: FDA Orange Book, application 022204. Patent numbers open the patent on Google Patents.

Patent Challenges to Gelnique

The first patent challenge to Gelnique reached the FDA in June 2014, from one company on that first day. The FDA approved a first challenger’s generic in May 2018, and the list records no sale by a first challenger yet.

What Is a Patent Challenge?

A generic company that wants to sell its version before Gelnique’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.

Patent challenges on the FDA’s list (1)
Product	First challenged	Companies that day	180-day head start	First challenger’s generic		Challenged patents run to
Product	First challenged	Companies that day	180-day head start	Approved	On sale	Challenged patents run to
Gel, 0.1	June 2014	1 company	Head start no longer applies decided June 2020 Earlier: decision deferred, June 2019	May 2018	Not yet	April 2020

Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.

Who Is Lined Up to Make Generic Oxybutynin Chloride

Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.

Applied to the FDA

One company has applied to the FDA to make generic oxybutynin chloride.

The FDA names a company only once it approves its application, even tentatively, and it has not done that for this one yet, so the company is not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.

First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.

Generic companies have challenged Gelnique’s patents with the FDA since June 2014: see the patent challenges.

Approved by the FDA

Not yet. The FDA has not approved a generic oxybutynin chloride. Final approval often comes close to the day a generic can be sold.

For Sale in Pharmacies

Not yet. No company lists a generic oxybutynin chloride for sale with the FDA.

Generic versions the FDA has approved (1 company)
Company	First approved	Strengths	Rated
Chartwell Rx Sciences LLC discontinued	May 2018	10% (100MG/PACKET)	–

Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).

Gelnique Price: What Pharmacies Pay and What Generics Usually Do

What a Generic Could Cost

How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Gelnique, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).

Brandbefore generics

1 makerabout 31% less

2 makersabout 44% less

4 makersabout 73% less

6+ makersover 95% less

Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.

Gelnique Strengths and Forms

Strength	Form	How it is taken	Approved	Status
10% (100MG/PACKET) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	Gel	Transdermal	January 2009	Discontinued reference product

Source: FDA Orange Book, Abbvie Inc. Listed for sale today by Allergan, Inc. (FDA NDC Directory).

Gelnique NDC Codes and Packages

Each Gelnique package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.

Gelnique packages (1)
NDC	Product	Package	Company
00023-5861-11	100 mg/g gel	carton of 30 packets of 1 g	Allergan, Inc.

Source: the FDA NDC Directory, current listings only. Only packages sold under Gelnique’s own FDA approval (NDA 22204) are listed, never a generic. Some codes belong to companies that repackage Gelnique: it is the same medicine in a different package.

What a Generic Gelnique Means for You

Nothing Changes Until It Is in Pharmacies

Until a generic is actually for sale, keep filling Gelnique as usual. When one arrives, there is nothing you need to sign up for.

Your Pharmacy May Switch You Automatically

Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.

It Will Probably Look Different

US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.

Your Insurance May Change Too

Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.

Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Gelnique”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.

Ask a pharmacist about Gelnique

Questions people ask about Gelnique

Is there a generic for Gelnique right now?

No. As of October 9, 2026 no generic oxybutynin chloride is listed for sale in the FDA NDC Directory. 1 generic version is FDA-approved (Orange Book), which usually means it is waiting on patents or on the maker’s own launch plans.

When will Gelnique go generic?

There is no expected month yet. The brand company and a generic maker settled their patent fight and agreed on when a generic can launch.

Will generic oxybutynin chloride be the same as Gelnique?

Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.

How much will the generic cost?

Nobody can say for sure before launch. One company has applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 31% less once one company sold a generic. That is a pattern from past launches, not a prediction for this one.

Has the FDA approved a generic Gelnique?

Not yet. The FDA Orange Book lists no approved generic version of Gelnique that is still marketed.

When does the Gelnique patent expire?

The FDA Orange Book lists 3 patents for Gelnique; the last runs to March 2031. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (a date that is not known yet) weighs all of that.

Has anyone challenged the Gelnique patents?

Yes. The first patent challenge to Gelnique reached the FDA in June 2014, from one company on that first day. The FDA approved a first challenger’s generic in May 2018, and the list records no sale by a first challenger yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.

Changes to This Projection

October 2026First generic expected a date that is not known yet on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.

Every change to the expected month is logged here with the month we saw it.

Also Going Generic

All upcoming generics

About Gelnique

Generic name oxybutynin chloride
How it is taken Skin patch
Company Abbvie Inc
Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
Patent challenges Since June 2014 (FDA)
More drugs Brand-name drugs starting with G
Have a question? A pharmacist answers, free. Ask about Gelnique

Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.